Navigation Links
Intercell in Medical News

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...r Bavituximab II-60 Jenken to Commence Phase II Trial of JBK-122 II-60 Pevion Biotech Initiates Phase I Study of Hepatitis C Vaccine II-61 intercell Releases Phase II Findings of IC41 II-61 6. Recent Industry Activity II-62 Three Rivers Acquires Infergen(R) II-62 International Consolid...

Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC's Advisory Committee on Immunization Practices

...gth of visit ATLANTA, June 24 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that the U.S. Cente...able in the United States. IXIARO was developed by intercell AG; the rights to market and distribute the vaccin... study with JE-VAX(R). About intercell AG ...

Intercell to Webcast Research & Development Day on Thursday, June 4, 2009

...ENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it will webcas...tious disease and the primary investigator for the intercell Travelers' Diarrhea Phase II clinical trial. Dr. D...rs. In addition to Dr. DuPont, members of the intercell management team will make presentations including,...

Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military

... - Exclusive, multi-year contract executed by intercell and U.S. Department of Defense for purchase of IXI... soon VIENNA, May 8 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL; OTC Bulletin Board: INRLY) announce...as follows: Exclusive contract for intercell to supply DLA with all their requirements for JE v...

Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis

... is a result of an excellent collaboration between intercell and the Walter Reed Army Institute of Research in ...ry VIENNA, March 31 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL) today announced FDA approval of its...ant contribution towards development of IXIARO and intercell is very appreciative of this outstanding collabora...

Huntsworth plc Releases Interim Statement on First Quarter 2008

...n. New European clients for Huntsworth Health include Daiichi-Sankyo, Pfizer and Novartis Vaccines, and global accounts won include Roche, Novartis, intercell and Iroko. Our multi-disciplinary business is also increasing, and whilst most clients still offer new projects and pitches in one area (advertising o...

Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT

...l/ -- Iomai Corporation (Nasdaq: IOMI ) today said that it will host a conference call and live webcast tomorrow to discuss today's announcement that intercell AG (VSE: ICLL) and Iomai have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a...

Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008

...l Development, Genentech * David P. Meeker, MD, President, LSD Therapeutics, Genzyme * Eszter Nagy, MD, PhD, Vice President, Pre-clinical R&D, intercell * Steve J. Offord, PhD, Vice President CNS New Products Marketing, Market Access and Business Development, sanofi-aventis * Carlos Plata-Salam...

Intercell to Begin Phase II JE Vaccine Trials in India

... Austrian biotech major, intercell and its partner Hyderabad-based Biological E. Ltd. announced that they have obtained regulatory clearance to start// a pediatric phase II clinical tri...
Intercell in Medical Technology

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

...ENNA and GAITHERSBURG, Md., May 28 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it has advance...luenza vaccines," stated Thomas Lingelbach, COO of intercell AG and CEO of intercell USA. "The recent H1N1 influenza situation certainl...

Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine

...orted by PATH VIENNA, April 7 /PRNewswire/ -- intercell AG (VSE: ICLL) announced today that a Phase I clin...ase I trial. Under the terms of the collaboration, intercell will develop the vaccine and make it available at ...is and Otitis media in young children. About intercell AG ...

Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

... WILMINGTON, N.C., Jan. 19 /PRNewswire/ -- intercell AG has retained Inclinix, Inc., to recruit volunte...ginning in April 2009. "We are pleased that intercell AG has chosen Inclinix as their partner for the TD...erious adverse events were reported. About intercell AG ...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

... VIENNA, Austria, Dec. 11 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced the execution of a ...or Intercell's Pandemic Influenza program. intercell is developing a Pandemic Influenza Vaccine Patch S...luenza vaccine, coupled with a single 50-microgram intercell patch was sufficient to provide an immune response...

Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

... VIENNA, Austria, Sept. 3 /PRNewswire/ -- Today, intercell AG (ICLL) announced the six months follow up data ...sting and future HCV combination treatments. Thus, intercell will follow its development strategy that will als...seen to expand to about EUR 3.5bn by 2006. About intercell AG ...

Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection

... VIENNA, Austria, Aug. 28 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that its collaborat...based on a conserved protein antigen discovered by intercell and licensed to Merck & Co., Inc. in 2004 on an ex...clinical development, manufacturing and marketing. intercell is eligible to receive milestone payments and roya...

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine

...el syndrome." As previously announced, Iomai and intercell AG (VSE: ICLL) have entered into an agreement wher...tered into an agreement with Intercell AG in which intercell will acquire Iomai for $6.60 a share. Some matte... to use; that the proposed acquisition of Iomai by intercell does not close or that the companies may be requir...

Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation

... - intercell AG ('Intercell') to acquire Iomai Corporation ('Io...y major shareholders for approximately 1.7 million intercell shares (representing approximately four percent ...chnology in the industry. Through the transaction intercell gains access to a further product ...

Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

... VIENNA, Austria, May 18, 2007 – intercell AG (VSE, “ICLL”) has been informed by ... increasingly difficult and challenging. About intercell AG: Intercell AG is a growing biotechnology company which focuses on the design and intercell AG is a growing biotechnology company which focus...
Intercell in Biological Technology

Iomai Stockholders Approve Merger With Intercell Subsidiary

GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) announced today that its stockholders approved the merger of Iomai with a wholly-owned subsidiary of Intercell AG. Approximately 71.6 percent of Iomai's outstanding shares entitled to vote at the special mee...

Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today

GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) announced that its Chief Scientific Officer, Gregory Glenn, M.D., and Alexander Von Gabain, Ph. D., the Chief Scientific Officer of Intercell AG (VSE: ICLL), will speak today at the Biotechnology...

Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis

...December 2008 VIENNA, April 2 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that its new vaccin... study with JE-VAX(R). About intercell AG intercell AG is an innovative biotechnology company that des...

Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine

... VIENNA, March 31 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it will host a...d Thomas Lingelbach (COO and Managing Director intercell Biomedical Ltd., Scotland) Dial-In: Austr... and an operator will then put you through to the intercell conference call. The presentation will be mad...

Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis

... for Q2 2009 VIENNA, March 30 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that the U.S. Food ...d certain other markets in Asia and Latin America. intercell will directly distribute and market IXIARO to the ... study with JE-VAX(R). About intercell AG ...

Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis

...VIENNA, Austria, Jan. 23 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL) today announced that the Australian...egulatory approval for the vaccine in any country. intercell has been successfully advancing parallel regulator...uinea and Pacific Islands (trade name JESPECT(R)). intercell is committed to make JESPECT(R) available to the A...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... FAES FARMA SA (SIBE Spain: FAE) GPC BIOTECH AG (NASDAQ: GPC ) GRIFOLS SA (SIBE Spain: GRF) H LUNDBECK A/S (OMX Nordic Exchange Copenhagen: LUN) intercell AG (Wiener Bourse, Austria: ICLL) RICHTER GEDEON NYRT (Budapest, Hungary: RICHTBO) STADA ARZNEIMITTEL AG (Frankfurt, Germany: SAZ) ZELTIA SA (SIBE ...

Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis

...technology with regard to the use of certain fusion proteins in the development of a tuberculosis vaccine. The license from SSI includes access to the intercell IC31(R) adjuvant. If the development is successful, sanofi pasteur would manufacture the vaccine commercially. SSI TB vaccine candidates are recombi...
Intercell in Biological Dictionary

Antigens

...n... Information about Antigens in the free online English dictionary and encyclopedia. ... Kirin Brewery Introduces Pneumococcal Antigens from intercell AG, ... by ... The antigens are located on the surface of the red blood cells and the ... in the A+ blood bind the antigens in the B+ blood a...
Other Tags
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... 17, 2015 As a board-certified orthopedic ... new offering of platelet-rich plasma (PRP) and ... is known for its world-class care of injury-caused ... surgical experience lacking in many other physicians offering regenerative ... are utilized for pain management and rehabilitation. Dr. Meier ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
(Date:4/17/2015)... Baptist Health and The University of Texas MD ... to transform oncology care in northeast Florida and southeast ... a joint cancer program to enhance patient access to ... Anderson Cancer Center is anticipated to open in the ... coordinated, multidisciplinary cancer care for adults in the region. ...
(Date:4/17/2015)... York, NY (PRWEB) April 17, 2015 ... collaborating with a multicenter team of U.S. and ... of bacteria yet in humans among an isolated ... jungles of Venezuela. Bacterial diversity in the Yanomami, ... found to be nearly double that of people ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
Other Contents